Study The effect of DARVYADIGHANVATI IN exessive per vaginal bleeding during menstrual cycle in PUBERTY .

Randomized Open Controlled Clinical Study To Evaluate Efficacy Of Darvyadighanvati In Asrugdara W.S.R.To Puberty Menorrhagia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/07/026517

Enrollment

125

Registered

2020-07-13

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E308- Other disorders of puberty

Interventions

Intervention1: Darvyadighanvati: Darvyadighanvati 500mg BD after meal for three months Control Intervention1: Norethesteron: Norethesteron 0.5mg TID for 7days followed by BD for 7 days followed by

Eligibility

Inclusion criteria

Inclusion criteria: Age 13 yrs to 19 years Patients with prolonged cycles, excessive bleeding p/v during menstruation, more than three pads Dysfunctional Uterine Bleeding Hb% 8 grams% and above

Exclusion criteria

Exclusion criteria: H/o Endocrinal disorders H/o Bleeding dyscrasias Intermenstrual bleeding H/o Structural abnormality in genital organs H/o Any other systemic illness H/o Genital tuberculosis PCOD Hb% H/o Juvenile Diabetes Mellitus

Design outcomes

Primary

Measure	Time frame
minimize exessive bloodloss in Asrugdhara (Puberty menorragia)Timepoint: 15 weeks	—

Secondary

Measure	Time frame
TO Minimize Excessive Blood Loss . An Alternative Hormonal Therapy In Puberty MenorrhagiaTimepoint: whiten three month of period	—

Countries

India

Contacts

Public ContactDrKavita Chandrashekhar Mule

MUHS Nashik

dr.jayashrisdeshmukh@gmail.com9325580777

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026